Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint Pharmaceuticals (NASDAQ: EYPT) reported total revenues of $7.5 million for Q1 2020, up from $2.0 million in Q1 2019. Net product revenues reached $4.7 million, driven primarily by $3.6 million from YUTIQ and $1.1 million from DEXYCU. Operating expenses increased to $18.9 million, leading to a net loss of $13.2 million or $0.11 per share. The company has initiated GLP toxicology studies for its EYP-1901 treatment and expects to file an IND application later this year. Cash reserves stand at $26.3 million, supporting operations amid COVID-19 challenges.